Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 (Nintedanib) Food Effect Study in Healthy Volunteers
NCT02182076Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2005
- Primary completion
- Nov 2005
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of nintedanib in idiopathic pulmonary fibrosis (IPF) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve in plasma over time from zero time extrapolated to infinity at 48 hours and Maximum observed concentration in plasma at 48 hours. Started Oct 2005; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02182076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182076.